Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease.
2021
Myostatin is a negative regulator of skeletal muscle and has become a therapeutic target for muscle atrophying disorders. Although previous inhibitors of myostatin offered promising preclinical dat...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
42
References
0
Citations
NaN
KQI